Equities research analysts expect Chimerix Inc (NASDAQ:CMRX) to report $810,000.00 in sales for the current quarter, Zacks reports. Three analysts have issued estimates for Chimerix’s earnings, with the lowest sales estimate coming in at $500,000.00 and the highest estimate coming in at $1.00 million. Chimerix reported sales of $1.98 million in the same quarter last year, which indicates a negative year-over-year growth rate of 59.1%. The company is scheduled to report its next quarterly earnings results on Thursday, March 1st.
On average, analysts expect that Chimerix will report full-year sales of $810,000.00 for the current fiscal year, with estimates ranging from $2.65 million to $3.65 million. For the next fiscal year, analysts expect that the company will post sales of $3.75 million per share, with estimates ranging from $1.00 million to $6.25 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Chimerix.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. Chimerix had a negative net margin of 1,440.67% and a negative return on equity of 26.00%. The firm had revenue of $0.90 million for the quarter, compared to the consensus estimate of $0.81 million.
Chimerix (NASDAQ:CMRX) opened at $4.93 on Thursday. Chimerix has a 1-year low of $4.17 and a 1-year high of $6.64. The firm has a market cap of $229.04, a price-to-earnings ratio of -3.45 and a beta of 1.46.
In other news, insider Linda M. Richardson sold 19,833 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $4.47, for a total value of $88,653.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.40% of the company’s stock.
Several hedge funds have recently made changes to their positions in CMRX. Voya Investment Management LLC raised its holdings in shares of Chimerix by 18.3% in the second quarter. Voya Investment Management LLC now owns 29,203 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 4,526 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Chimerix by 8.3% in the second quarter. The Manufacturers Life Insurance Company now owns 39,628 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 3,042 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Chimerix by 7.3% in the second quarter. Rhumbline Advisers now owns 48,541 shares of the biopharmaceutical company’s stock valued at $265,000 after purchasing an additional 3,300 shares during the last quarter. Nationwide Fund Advisors raised its holdings in shares of Chimerix by 70.3% in the third quarter. Nationwide Fund Advisors now owns 60,567 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 24,994 shares during the last quarter. Finally, Alliancebernstein L.P. raised its holdings in shares of Chimerix by 8.3% in the second quarter. Alliancebernstein L.P. now owns 70,200 shares of the biopharmaceutical company’s stock valued at $383,000 after purchasing an additional 5,400 shares during the last quarter. Institutional investors own 70.32% of the company’s stock.
WARNING: “Zacks: Analysts Anticipate Chimerix Inc (CMRX) Will Post Quarterly Sales of $810,000.00” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2018/01/18/zacks-analysts-anticipate-chimerix-inc-cmrx-will-post-quarterly-sales-of-810000-00.html.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.